Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

As reported by manilatimes.net

If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rar...

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on manilatimes.net ↗

Market Samachar is a news aggregator. This article was originally published by manilatimes.net. Tap the button above to read the full story on their site.

COMPANIES Citi initiates coverage on 4 Indian power equipment stocks; sees up to 33% upside. Own any? Stocks-Markets-Economic Times
COMPANIES Reliance traders said to game plan in case RBI raises rates Stocks-Markets-Economic Times
INDIAN Dollar at two-month high as Gulf hostilities flare, yen near intervention zone Markets-Economic Times
INDIAN ICICI Bank share price: Motilal Oswal sees 41% upside. Should you buy? mint - markets
INDIAN SMR Jewels IPO allotment to be finalised today. Here's GMP and steps to check status mint - markets
GLOBAL Kalshi wants small businesses to hedge like Wall Street. A NYC bar is trying it with Knicks promotion CNBC
INDIAN Cutting Costs, Not Experiences: The Balancing Act Of Indian Households Amid Global Uncertainty NDTV Profit - Latest
INDIAN Maruti Suzuki Flex Fuel Car Launched: Price, Features, Mileage, Colours & Other Details NDTV Profit - Latest

Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

More from Market Samachar